chemieunternehmen.com

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-its-neurodegeneration-collaboration-with-bristol-myers-squibb-6014

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partners-with-alloy-therapeutics-to-expand-its-antibody-discovery-platform-6010

Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/autobahn-labs-and-ucsf-announce-strategic-drug-discovery-collaboration-6012

Evotec SE today announced that the Company has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-key-milestones-in-its-collaboration-with-bristol-myers-squibb-on-targeted-protein-degradation-6008

Evotec SE and the life science company Sartorius announced today that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sartorius-partner-with-start-up-curexsys-on-ipsc-based-exosome-approach-6006

The 10th edition is dedicated to our newly developed next generation transcriptomics toxicology platform, a truly translational project across different groups at Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-10—evotecs-transforming-transcriptomics-toxicology-platform-6004